Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Next Previous
X
Search
Trial Profile

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Divesiran (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SANRECO; SLN
  • Sponsors Silence Therapeutics

    • Most Recent Events

    • 09 Dec 2024 Results presented in a Silence Therapeutics media release.
    • 09 Dec 2024 According to a Silence Therapeutics media release, first subject in the Phase 2 portion of the study has been dosed.
    • 09 Dec 2024 According to a Silence Therapeutics media release, additional results from the Phase 1 open label portion of the study were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top